VANCOUVER, (July 21, 2021) Segra International Corp. ("Segra"), a Canadian agriculture technology company, is pleased to announce the successful shipment of over 3,000 Cannabis plantlets comprised of seven unique cultivars to one of the three largest cannabis companies in the world.
With this order, Segra is collaborating with their client on the trial of various premium cultivars intended to diversify the client's product portfolio. The client plans to use these plantlets to validate the inherent efficiencies of utilizing plant tissue culture to outsource internal propagation efforts, maximize flowering canopy, and reduce operating expenses.
As part of Segra's Verified Segra Stock™ guarantee, these plantlets were DNA fingerprinted and screened intensively for known plant pathogens and diseases utilizing Segra's best-in-class quality assurance program. Starting with this input material supports the growing of replicable crops and provides the grower certainty they will receive the same standardized input material with each shipment. Furthermore, the application of VNTR DNA fingerprinting technology can be used throughout the supply chain for track and trace purposes, from plantlet to flower, which can provide both producers and consumers with much-needed confidence regarding cultivar consistency order-after-order.
"With competition increasing in the Canadian and international markets and continued growth in demand for high THC products, Segra is offering a solution for producers to maintain competitiveness by offering proprietary, high-value genetics through a premium tissue cultured format," said Jamie Blundell, Segra's Chief Executive Officer. "Segra's tissue culture processes, pathogen detection tests, and quality control systems represent the emerging gold standard for modern cannabis operations. We look forward to working with this client and other producers around the world to showcase how better plants lead to better products and profits."
Learn more about Segra's services and premium cultivars by viewing the 2021 Cultivar and Services Catalogue.
About Segra International:
Segra is an agriculture technology company offering plant tissue culture, plant genomics, and pathogen detection services to accelerate the advancement of the cannabis industry. The company's proprietary technologies empower its clients to drive financial performance and mitigate risk while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce Verified Segra Stock™, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally. Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, plant tissue culture, and regulatory compliance to support this vision. Learn more at segra-intl.com or view the 2021 Cultivar and Services Catalogue.
For Further Information:
- Segra International
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by applicable law.